Immediate Radical Therapy or Conservative Treatments When Meeting the Milan Criteria for Advanced HCC Patients After Successful TACE

Journal of Gastrointestinal Surgery

Volumn 18, Issue 6, 2014, Pages 1125-1130

  Jiang, L ^a   Lei, J Y ^a   Wang, W T ^a   Yan, L N ^a   Li, B ^a   Wen, T F ^a   Xu, M Q ^a   Yang, J Y ^a   Wei, Y G ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Conservative treatments; Hepatocellular carcinoma; Radical therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; MITOMYCIN;

ADULT; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION; COMPARATIVE STUDY; FEMALE; HUMAN; LIVER NEOPLASMS; LIVER RESECTION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATHOLOGY; PRACTICE GUIDELINE; RETREATMENT; SURVIVAL RATE; TIME; TUMOR RECURRENCE; WATCHFUL WAITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; DOXORUBICIN; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; RETREATMENT; SURVIVAL RATE; TIME FACTORS; WATCHFUL WAITING;

EID: 84901449843     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-014-2508-2     Document Type: Article

References (29)

1. Nordenstedt H, White DL, EI-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42 Suppl 3: S206-14.
2. Kin JM, Kwon CH, Joh JW, et al. Patients with unresectable hepatocellular carcinoma beyond Milan criteria: should we perform transarterial chemoembolization or liver transplantation? Transplant Proc. 2010;42(3): 821-4.
3. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trail of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35: 1164-71.
4. Llovet JM, Real MI, Montana X, Barcelona Liver Cancer Group, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359;1734-9.
5. Yao FY, Kerlan Jr RK, Hirose R, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008;48: 819-27.
6. Gordon-Weeks AN, Snaith A, Petrinic T, et al. Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria. Br J Surg. 2011;98(9): 1201-8.
7. Herrero JI, Sangro B, Pardo F, et al. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl. 2008;14: 272-8.
8. Yao FY, Kinkhabwala M, LaBerge JM, et al. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant. 2005;5(Pt1): 795-804.
9. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42: 1208-36.
10. Silva M, Moya A, Berenguer M, et al. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl. 14: 1449-60.
11. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334: 693-9.
12. Chapman WC, Majella Doyle MB, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg. 2008;248(4): 617-25.
13. Jiang L, Yan L, Li B, et al. Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant. 2010;10(8): 1861-9.
14. Radionics TM, Burlington MA, Lei JY, Yan LN, Wang WT. Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy. World J Gastroenterol. 2013;19(27): 4400-8.
15. Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, Xu Y, Zeng Y. A randomized trial comparing radiofrequency ablation and surgical resection for HCC confirming to the Milan criteria. Ann Surg. 2010;252(6): 903-12.
16. Lei J, Wang W, Yan L. Surgical resection versus open-approach radiofrequency ablation for small hepatocellular carcinomas within Milan criteria after successful transcatheter arterial chemoembolization. J Gastrointest Surg. 2013 17(10): 1752-9.
17. Herber S, Schneider J, Brecher B, et al. TACE: therapy of the HCC before liver transplantation-experiences. Rofo. 2005;177(5): 681-90.
18. Lei J, Yan L. Comparison between living donor liver transplantation recipients who me the Milan and UCSF criteria after successful downstaging therapies. J Gastrointest Surg. 2012;16(11): 2120-5.
19. Lei J, Wang W, Yan L. Downstaging advanced hepatocellular carcinoma to the Milan criteria may provide a comparable outcome to conventional Milan criteria. J Gastrointest Surg. 2013;17(8): 1440-6.
20. Yao FY, Xiao L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007;7(11): 2587-96.
21. Lei JY, Wang WT, Yan LN. Up-to-seven criteria for hepatocellular carcinoma liver transplantation: a single center analysis. World J Gastroenterol. 2013;19(36): 6077-83.
22. Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85(12): 1726-32.
23. Lei JY, Yan LN, Wang WT. Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy. World J Gastroenterol. 2013;19(27): 4400-8.
24. Vitale A, D'Amico F, Frigo AC, et al. Response to therapy as a criterion awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. Ann Surg Oncol. 2010;17(9): 2290-302.
25. Bargellini I, Bozzi E, Campani D, et al. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol. 2013;82(5): e212-8.
26. Toso C, Menth G, Kneteman NM, Majno P. The place of downstaging for hepatocellular carcinoma. J Hepatol. 2010;52(6): 930-6.
27. Otto G, Schuchmann M, Hoppe-Lotichius M, et al. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE. J Hepatol. 2013;59(2): 279-84.
28. Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: A systematic review. Liver Cancer. 2012;1(3-4): 144-58.
29. Teizi E, Golfieri R, Piscaglia F, et al. Response rate and clinical outcome of HCC after first and repeated C TACE performed "on demand". J Hepatol. 2012;57(6): 1258-67.